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Edited by Richard MaraisAbstract Cell survival is maintained by growth factors and
critically depends on suﬃcient energy supply. New evidence
suggests that a rise in cellular energy production is not merely a
homeostatic response to increased demand but subject to
regulation by extrinsic factors. The mechanisms operating in
this control are largely enigmatic. Work on transformed cells
identiﬁed direct targeting of glycolytic enzymes by signaling
proteins as one possibility. But mitochondrial oxidative phos-
phorylation and biogenesis may also be subject to regulation by
growth and survival factors. Both, positive and negative regula-
tors of cell survival impinge on the processes of cellular energy
production to regulate growth and survival versus death.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis, the predominant form of physiological cell death
during development and adult life, occurs via a tightly or-
chestrated sequence of events. Central to this process is the
activation of caspases through death receptor stimulation
(extrinsic pathway) or the breakdown of mitochondrial integ-
rity and the release of apoptogenic factors (intrinsic pathway)
[1]. By degrading structural and other proteins, caspases ini-
tiate and execute the demise of the cell. The main components
of the apoptotic machinery are constitutively expressed in all
cells and guarded against the accidental activation through
spatial separation and the expression of inhibitory proteins.
Bcl-2 maintains the intactness of the outer mitochondrial
membrane to prevent the release of apoptogenic factors [2],
whereas the protective function of IAP proteins extends be-
yond caspase activation [3]. Extrinsic factors play a key role in
the control of cell survival and anti-apoptotic activity has been
demonstrated for all canonical signaling pathways. Two of the
best studied survival pathways, the cytoplasmic (Ras-Raf-
MEK-ERK) [4] and the PI3K (PI-3 kinase)-PKB (protein ki-
nase B) [5] pathway, exert their eﬀects through transcriptional
and post-transcriptional regulation of these and other survival* Corresponding author. Fax: +43-512-504-24625.
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doi:10.1016/j.febslet.2004.10.021proteins (Fig. 1A and B). Suppression of caspase activation or
activity is critical for survival in the face of an immediate
threat to the cell. However, the maintenance of cellular energy
homeostasis during routine as well as situations of enhanced
demand is equally important for cell survival. An increasing set
of data supports the idea that survival pathways critically
regulate the processes of cellular energy production and
management.2. Sensing nutrients and oxygen
Availability of nutrients and oxygen determines the com-
petence of a cell to respond to exogenous stimuli with prolif-
eration, survival, diﬀerentiation or even death. Work of the
last years has laid out the framework for our understanding of
the sensory systems, which allow the cell to decipher envi-
ronmental clues. Cellular energy production occurs through
the conversion of ADP to ATP during glycolysis and oxidative
phosphorylation. Maintenance of a high ATP to ADP ratio is
essential and changes in the ADP/ATP and more importantly
the AMP/ATP ratio are sensitive indicators of the cellular
energy status [6] (Fig. 1C). A rise in the AMP/ATP ratio
triggers the activation of AMPK (AMP-activated protein ki-
nase), which terminates ATP-consuming metabolic pathways
and switches on ATP-generating systems, including glycolysis,
fatty acid oxidation and glucose uptake [7]. AMPK interacts
with the tumor suppressor TSC2 (hamartin), which together
with TSC1 (tuberin) functions as an antagonist of the mTOR
signaling pathway [8], a central controller of cell growth in
response to growth factors, cellular energy and nutrient levels
[9]. The survival kinase PKB in turn activates mTOR signaling
by directly phosphorylating and inactivating TSC2 [10,11].
AMPK, on the contrary, binds, phosphorylates and thereby
enhances TSC2 function [12]. This mechanism represents a
convergence point of nutrient sensing and survival signaling.
Little is known about the upstream regulators of AMPK.
LKB1, whose inactivation provides the genetic basis for the
Peutz–Jeghers syndrome, a familial colorectal polyp disorder
[13], was shown to phosphorylate and activate AMPK [14].
Mouse embryonic ﬁbroblasts deﬁcient in LKB1 display hy-
persensitivity towards apoptosis induction by treatments that
elevate AMP. Moreover, these cells exhibit elevated signaling
downstream of mTOR, demonstrating that LKB1 functions in
negative regulation of mTOR [15].blished by Elsevier B.V. All rights reserved.
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Fig. 1. Mitogenic signaling cascades govern cell survival by controlling cellular energy homeostasis. Individual signaling entities discussed for their
involvement in the control of cellular energy production and consumption are grouped (gray shaded areas) and labeled (A)–(E). (A) Mitogenic
signaling cascades control cell survival through transcription-dependent and -independent mechanisms and increasing evidence, presented in this
review, suggests that they also directly govern cellular energy metabolism. The dashed arrow at the bottom of these signaling cascades illustrates that
proteins signaling through these pathways or being part of them frequently are encountered in or at the mitochondria. (B) Phosphorylation of the
protein BAD, normally residing at the outer mitochondrial membrane, has been described for C-Raf and PKB. Modiﬁed BAD binds to cytoplasmic
14-3-3 proteins and thereby looses its negative impact on cell survival. New work suggest that mitochondrial BAD is required in addition for the
assembly of a large protein complex that also contains glucokinase. (C) Lack of nutrients leads to an increase in the AMP/ATP and activation of
AMPK. As a consequence, ATP-consuming processes are shut down and ATP generation is stimulated. Signaling downstream of AMPK results in
the repression of mTOR, a central controller of growth, which can be antagonized by mitogen-activated PKB. (D) Lack of oxygen also results in the
HIF-1 dependent compensatory upregulation of factors required for increased glycolysis and formation of new blood vessels. (E) These processes are
also regulated through oxygen-independent regulation of HIF-1 via mitogenic signaling cascades.
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scription factor composed of a constitutively expressed HIF-1b
and a HIF-1a subunit, whose expression is highly regulated by
oxygen-dependent (mainly aﬀecting the degradation of the
protein) and oxygen-independent (regulating mainly the syn-
thesis) mechanisms [16,17] (Fig. 1D). HIF-1 target genes are
involved in organismic responses to condition of low oxygen
(e.g., the formation of new blood vessels or the expansion of
erythrocytes) and alterations in cellular metabolism [16].
Degradation of HIF-1-a under normoxic conditions results
from an O2-dependent prolyl-hydroxylation of HIF-1a, in-
teraction with the tumor suppressor protein VHL and prote-
asomal targeting of HIF-1a. Since O2 is a limiting substrate in
this reaction, this post-translational regulation of HIF-1a
levels directly links oxygen availability to HIF-dependent
regulation of gene products involved in the response to hy-
poxia [17]. Oxygen-independent regulation of HIF-1 through
mitogens is the second major mechanism regulating the ex-
pression of this protein and allows the cells to respond to in-
creasing energy demands during growth processes (Fig. 1E).
Both, PI3K/PKB and the cytoplasmic signaling cascade have
been implicated in the expression of the HIF-1 [17] and they
may also contribute to increased HIF-1 protein levels seen in
tumors [17].3. Evidence for extrinsic control of cellular energy production
A ﬁrst strong hint for a link between mitogenic signaling and
metabolism came from the analysis of tumor cells. Mutationsin components of mitogenic cascades render them largely in-
dependent of the control by extrinsic factors and result in
constitutive activation of survival and growth pathways. In-
crease in tumor size limits oxygen supply through mere diﬀu-
sion [17]. This lack is compensated by the transcriptional
upregulation of angiogenic factors via mitogen signaling and
by metabolic alterations. As ﬁrst realized by Warburg [18],
tumors commonly rely on glycolysis under aerobic conditions
as a means for energy production. This glycolytic switch is
driven by the deregulated mitogenic cascades, which through
HIF-1-dependent and HIF-1-independent mechanisms upre-
gulate the expression of components of the glycolytic ma-
chinery [19]. Additionally, oncogenes may directly regulate the
activity of key metabolic enzymes [20,21]. The critical role for
HIF-1 in cellular transformation is underscored by the
resistance of HIF-1a-deﬁcient ES cells to teratocarcinoma
formation [22].
Mitochondrial oxidative phosphorylation is the predomi-
nant mechanism for energy generation under aerobic condi-
tions in the organism, but possibly not in all cultured cells [23].
ATP is produced in a process in which electrons, initially
generated from NADH and FADH2, are passed along a series
of carrier molecules and enzymes (electron transport chain)
and ultimately are transferred to molecular oxygen [24]. Cy-
tochrome c oxidase (COX) is the terminal oxidase of cell res-
piration. NADH and FADH2 are derived from the
metabolism of nutrients such as glucose and fatty acids. Sev-
eral published observations support the view that extracellular
signals directly participate in the regulation of oxidative
phosphorylation. Mitochondrial localization has been dem-
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Miyazaki et al. have shown that c-Src is present within the
mitochondria of osteoclasts, where it phosphorylates COX.
This Src-induced COX activity is required for the normal
function of these cells but not for their survival [27]. Mito-
chondrial presence has been reported for A-Raf [28] as well as
components of the NF-jB pathway [29].
With the advancement of organelle proteomics, an extensive
catalog of the mitochondrial proteome generated from highly
puriﬁed mitochondria of the normal human heart has been
compiled [30]. Among the 615 proteins identiﬁed in a recent
screen, a signiﬁcant portion is involved in cellular signaling.
This group comprises members as well as regulators of the
small GTPases of the Ras superfamily, subunits of heterotri-
meric G-proteins, mitogen-activated protein kinases (MAPK),
lipid kinases, and RSK [30]. As exempliﬁed by the PKB-
dependent association of hexokinase (HK) with the mito-
chondria [31], mitochondrial protein composition and perhaps
also posttranslational modiﬁcation of these proteins may be
subject to regulation by extrinsic signals. The reasons for the
extension of primarily cytoplasmic signaling cascades to and
into the mitochondria are currently unclear, and in almost all
cases we lack an understanding of the processes regulated by
them. For most non-mitochondrial proteins, the mitochondrial
interaction partners and the mechanisms regulating their in-
teraction or their uptake remain to be deﬁned. Analysis of Ras
signaling showed that this protein, which normally resides at
the inner surface of the cell membrane, also can be targeted to
the ER and the Golgi and initiate signaling from there [32].
The possibility thus has to be considered that mitochondria are
not only the endpoint of signaling pathways initiated at the cell
membrane or the cytoplasm, but that signaling proteins re-
siding at or in the mitochondria participate in mitochondrial
retrograde signaling and thereby aﬀect non-mitochondrial
processes [33].4. Integrating energy homeostasis and pro-survival signaling
Events, which precede the onset of apoptosis following
growth factor removal, are impaired glucose metabolism as a
result of glucose transporter downregulation and a reduction
in the ﬂux through the glycolytic pathway via direct eﬀect on
the localization or activity of glycolytic enzymes, collapse of
the inner mitochondrial membrane potential, release of cyto-
chrome c, and a drop in mitochondrial oxygen consumption.
Two diﬀerent mechanisms have been suggested to counteract
these events: cells protected by the antiapoptotic protein Bcl-2
adapt to lower rate in metabolism, PKB counteracts a decline
in metabolism, e.g., by increasing glucose uptake and stimu-
lating glycolysis [34]. Furthermore, PKB inhibits early apop-
totic events by increasing the mitochondria-bound HK
activity. Mitochondrial HK catalyzes the ﬁrst committed step
of glucose metabolism by phosphorylating glucose to glucose-
6-phosphate using ATP produced by mitochondria, thereby
coupling glycolysis and mitochondrial phosphorylation [31].
Also, the survival activity of oncogenic C-Raf may in part
depend on its eﬀects on mitochondrial energy production
through interference with the ﬂux of metabolites in and out of
the mitochondria. VDAC (voltage-dependent anion channel/
mitochondrial porin) [35] has been shown to interact with C-
Raf [36]. This work pointed to a potential negative regulatoryeﬀect of C-Raf on the mitochondrial reconstitution of VDAC,
a mechanism, which may limit the exchange of metabolites and
thereby indirectly gear cellular energy production towards
glycolysis [4,36].
Not only do survival pathways converge upon energy pro-
ducing processes but also proteins involved in the negative
control of survival. The pro-apoptotic function of BAD, a
BH3-only domain pro-apoptotic member of the Bcl-2 family,
is normally inactivated through phosphorylation by survival
kinases resulting in cytoplasmic relocalization [2] (Fig. 1B).
When residing at the mitochondria BAD is part of a large
protein complex that also contains glucokinase, which cata-
lyzes the ﬁrst step of glucose metabolism at the start of gly-
colysis or storage as glycogen. BAD is required to assemble
this complex and lack of BAD results in reduced mitochon-
drial respiration in response to glucose. Glucose deprivation in
turn results in dephosphorylation of BAD and apoptosis [37].
These ﬁndings again support the close interplay of cellular
metabolism and survival control (Fig. 1).5. Long-term adjustments
Short-term alterations in the composition and function of
mitochondrial proteins are instrumental in cell death/survival
decisions, but also enhanced mitochondrial biogenesis allows
cells to adapt to an increased demand for energy production
(long-term eﬀect). Mitochondrial protein composition is of
hybrid origin. Apart from a limited number of mitochondrially
synthesized proteins, the overwhelming majority of proteins is
encoded in the nucleus, synthesized in the cytoplasm and re-
quires mitochondrial import. Formation of new mitochondrial
proteins derived from nuclear and mitochondrial genomes is
tightly regulated by transcription factors, such as nuclear re-
spiratory factors 1,2 (NRF-1,2) or muscle-speciﬁc CREB and
YY1 [38]. Of particular importance are their co-activators,
PGC-1 (PPARc/peroxisome proliferators-activated receptor
coactivator-1) and PRC (PGC-1 related coactivator). Expres-
sion of PCG-1a by itself is suﬃcient to increase the number of
mitochondria in cardiac and skeletal muscle in transgenic mice
[39]. Expression and phosphorylation of PCG-1a are regulated
in response to key physiological regulators [38]. p38, a member
of the MAPK family, has been shown to phosphorylate PCG-
1a on three residues in a negative regulatory domain adjacent
to the transcriptional activation domain, resulting in the relief
on transcriptional repression. Since many cytokines stimulate
p38, this activation may increase PCG-1a activity allowing the
cells to cope with the increased energy expenditure [40]. These
coactivators thus could provide a link between extrinsic signals
and mitochondrial biogenesis.
Nitric oxide (NO), which is an important regulator of
proliferation and diﬀerentiation, also increases the expression
of PCG-1a leading to mitochondrial biogenesis [41]. Given
the important role of NO as a second messenger, this
mechanism thus may connect cytoplasmic signaling with the
regulation of mitochondrial processes. Most recently, it has
been shown that NRF-1 regulated genes are also functional
targets of the oncogene class transcription factor c-Myc [42].
c-Myc expression is rapidly induced by mitogenic signaling
[43], and it is possible that this physiological response may
establish a link between mitogen signaling and mitochon-
drial biogenesis.
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The outcome of signals transmitted in the cells is dictated by
the eﬀectors. To this end a mitochondria may represent a much
more heterogeneous population than previously anticipated.
Several published reports suggest that they not only diﬀer in
size, shape and number [44], but are biochemically and func-
tionally diﬀerent. Heterogeneity has not only been described
for mitochondria originating from diﬀerent cells and organs
[45], but also for mitochondria within the same cell [45–47].
The reasons for this are best understood in cases where this
reﬂects mitochondrial adaptation to speciﬁc energy demands
of the cell or to tissue-speciﬁc functions (steroidogenesis in
adrenal cortex; heme biosynthesis in bone marrow; and energy
production for contraction in oxidative muscles or for various
metabolic transformations in liver). Comparative proteomics
of mitochondria from heart, brain, kidney and liver revealed
that out of all potential or veriﬁed mitochondrial proteins only
50% are present in each individual tissue, suggesting the exis-
tence of a vast number of proteins, which allow mitochondria
to adjust to organ-speciﬁc tasks. In the discussion of the mi-
tochondrial heterogeneity within a single cell, the question
arises whether mitochondria are independently responding
units or functionally coupled parts of a network [46,48]. In the
context of the question(s) discussed here, it will be interesting
to see how intracellular functional compartmentalization can
be achieved and which mechanisms regulate subset-speciﬁc
responses to extrinsic challenges.
Signaling pathways postulated to function in the regulation
of cellular energy production are frequently altered in diseases
including cancer and other patho-physiological conditions
(e.g., ischemia/reperfusion). But also mutations in mitoc-
hondrially encoded proteins can be the underlying cause of
cardiomyopathies and other cytopathies, including diabetes,
obesity, neurodegeneration and even cancer [49,50]. Under-
standing how these changes aﬀect cellular metabolism and thus
also survival and proliferation, metabolic alterations contrib-
uting to these diseases may be instrumental for the design of
new therapeutic strategies in the treatment of these ailments.
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